Detection of an unusual G8P[8] rotavirus in a Rotarix-vaccinated child with acute gastroenteritis using Nanopore MinION sequencing

A case report

Jong-Hwa Kim, PhD a, Dae Yong Yi, MD, PhD b, Inseok Lim, MD, PhD b, Alan C. Ward, PhD c, Wonyong Kim, PhD a,*

1. Introduction

Rotaviruses are the major cause of diarrhea-associated hospitalization and death among children less than 5 years of age. Nearly 200,000 children die from rotavirus diarrhea each year. [1] Accurate and rapid diagnosis of rotavirus infection is important for the determination of appropriate treatment control of the spread of infection. Laboratory diagnosis of rotavirus infection is usually performed using diarrheal stool samples from symptomatic patients using enzyme immunoassays and reverse transcription polymerase chain reaction. [2] However, these methods are not always able to detect all rotavirus strains and have difficulty in distinguishing between wild-type and vaccine strains, a distinction which is crucial for clinical samples. [3,4] Furthermore, new rotaviruses (human and animal recombinant strains) have emerged, which cannot be detected by conventional methods. [5] These concerns have been raised about whether the rotavirus detection might fail to detect all rotavirus cases and thus lead to misdiagnosis of some cases. Nanopore MinION sequencing has been used to detect viruses, such as Ebola virus, [7] and a new recombinant hepatitis B virus. [8] However, the detection of rotavirus has not been reported. Here, we report the first application of Nanopore MinION sequencing for the diagnosis of rotavirus infection via the detection of an unusual human-bovine recombinant rotavirus causing a gastroenteritis for which the causative organism could not be detected by the usual diagnostic methods in a Rotarix-vaccinated child.

2. Case presentation

A 27-month-old girl patient was hospitalized for 4 days with severe gastroenteritis in January 2018 to the Department of
Pediatrics at Chung-Ang University Hospital (Seoul, South Korea). The patient had severe signs and symptoms, including vomiting (twice per day), diarrhea (twice per day), high fever (38.5°C), mild dehydration, and periumbilical pain. At the time, the patient had a hemoglobin level of 12.2 g/dL, a white blood cell count of 8280 cells/μL, an absolute neutrophil count of 5067 cells/μL, a serum C-reactive protein level of 19.6 mg/dL, an erythrocyte sedimentation rate of 21 mm/h, a serum aspartate aminotransferase level of 50 IU/L, and a serum alanine aminotransferase level of 20 IU/L. Of note, the patient was given the Rotarix vaccine in 2 doses at the ages of 2 and 4 months.

Stool samples were collected according to a protocol (#1710-009-303) approved by the Human Subjects Institutional Review Board of Chung-Ang University Hospital. Written informed consent was obtained from the parents of the infant enrolled in the study for data provision and publication of this case report.

The stool sample was pre-diagnosed as negative for rotavirus using an RIDASCREEN Rotavirus kit (R-Biopharm AG, Germany) and was negative for astrovirus, rotavirus, enteric adenovirus, and norovirus according to the Seeplex Diarrhea-V ACE Detection Assay (Seegene, Korea), from a stool specimen taken at a diagnostic laboratory in the Department of Laboratory Medicine of Chung-Ang University Hospital, Seoul, Korea. Moreover, stool culture confirmed that there was no growth of common diarrhea-causing bacteria, such as diarrheogenic Escherichia coli, Salmonella, Shigella, and Campylobacter.

To confirm the unexplained severe gastroenteritis patient, the stool specimen was immediately transported to the Department of Microbiology, Chung-Ang University College of Medicine. The stool sample was suspended in 10% phosphate buffered saline and centrifuged at 12,000 g for 15 minutes, and the supernatant was collected. Viral RNA was extracted from the supernatant after filtration through a 0.2 μm sterile syringe filter.
(Corning, Corning, NY) using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). The viral RNA was used to construct a library for Nanopore MinION sequencing [Oxford Nanopore Technologies, Cambridge, UK (Fig. 1A)]. FastQ files, generated by MinION sequencing, were used to assess sequence quality with poretools software (v. 0.6.0). The library was constructed, and low-quality sequences, which included adapter sequences and short reads (< 20bp), were trimmed using Geneious R10 (v.10.0.9). Phylogenetic analysis and amino acid identification were performed using MEGA X software.

A total of 144,406 sequence reads were obtained with a mean length of 514.9 ± 58.9 bp after trimming adapter sequences and filtering based on quality and read length (Fig. 1B). Of a total of 35,848 reads, 29,433 reads were aligned to virus sequences from the NCBI database and were matched to the human rotavirus genome (97.7% of virus reads) (Fig. 1C). The aligned sequences covered 11 segments of G8P[8] group A rotavirus and indicated a high genome coverage (%) with >95.0% of pairwise identity (Fig. 1D). The mapped reference sequence/total length of VP6, VP7, NSP2, and NSP3 showed a high coverage of 100.0% (Table 1). In addition, VP2, VP4, and NSP4 showed a coverage >95.0%. VP3 showed a coverage of 91.4% per mapped reference sequence. On the other hand, VP1, NSP5, and NSP1 showed a coverage of only 76.1%, 59.1%, and 40.0%, respectively. To classify the detected rotavirus strain (designated as CAU17L-79) within group A rotavirus, representative sequences from each segment were extracted, and a phylogenetic tree was constructed with each reference sequence. All 11 segments of the CAU17L-79 strain were aligned and mapped to

| Genes | Total length (bp) | Mapped Ref-seq (bp) | Coverage (%) | Pairwise identity (%) |
|-------|------------------|---------------------|--------------|----------------------|
| VP1   | 3302             | 2514                | 76.1         | 99.9                 |
| VP2   | 2693             | 2643                | 98.1         | 99.0                 |
| VP3   | 2591             | 2369                | 91.4         | 99.9                 |
| VP4   | 2366             | 2149                | 96.0         | 97.4                 |
| VP6   | 1356             | 1336                | 100          | 99.8                 |
| VP7   | 1062             | 1062                | 100          | 99.5                 |
| NSP1  | 1619             | 646                 | 40.0         | 82.4                 |
| NSP2  | 1029             | 1029                | 100          | 97.9                 |
| NSP3  | 1105             | 1105                | 100          | 99.5                 |
| NSP4  | 751              | 746                 | 99.3         | 98.6                 |
| NSP5  | 784              | 463                 | 59.1         | 93.2                 |

Figure 2. Phylogenetic tree of G8P[8] rotavirus based on nucleotide sequences obtained from MinION sequencing. The phylogenetic tree was constructed from 11 rotavirus gene sequences (VP7, VP4, VP1, VP2, VP3, VP6, NSP1, NSP2, NSP3, NSP4, and NSP5).
human G8P[8] rotavirus strains in GenBank: NP-130/2014 and KKL-17/2013 from Thailand, RVN1149/2014 from Vietnam, and SO1162/2017 from Japan. However, the VP7 gene was from bovine G8P[14] rotavirus (Cow 68/2007 and Cow-UP/2010 from India). The CAU17L-79 strain was found to possess the G8-P[8]-I2-R2-C2-M2-A2-N2-T2-E2-H2 genotype constellation for the VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-NSP4-NSP5/6 genes, respectively (GenBank accession no. MN058730-MN058740). Therefore, CAU17L-79 is a strain responsible for multiple reassortment events between the DS-1-like P[8] strains and bovine strains in Asia (Fig. 2). After the diagnosis of rotavirus infection by MinION sequencing, the patient was successfully treated by rehydration with low-osmolarity ORS solution and galtase powder with probiotics after 3 days.

3. Discussion

In 2006, 2 licensed vaccines, Rotarix, a human monovalent G1P[8] vaccine, (GlaxoSmithKline, Belgium) and RotaTeq, a pentavalent human-bovine reassortant vaccine (Merck & Co.) were used in more than 100 countries. Both Rotarix and RotaTeq have been found to be effective against common circulating strains such as the G1, G3, G4, and G9 strains of P[8]. However, these vaccines are not sufficient for protection against all rotavirus G and P serotypes, which are not included in the vaccine formulation.

It is of note that a G8P[8] rotavirus patient in this study was given Rotarix according to a standard schedule. The current rotavirus vaccines commercially available do not include this genotype. Considering that G8P[8] rotaviruses appear to be emerging in recent years, concerns have been raised about failures in preventing and diagnosing rotavirus infections, particularly in the post-vaccine era.

To overcome these limitations, large-scale complex genome sequencing for obtaining sequences for all 11 rotavirus RNA segments is needed. Nanopore MinION sequencing is an emerging third-generation sequencing technology, which offers rapid microbial identification. It has 2 advantages: the ability to perform real-time sequence analysis enable metagenomic species identification; and the capacity to obtain longer reads, offering simplified and less ambiguous genome assembly.

In this study, although the sample was pre-diagnosed as negative for various enteric microbes in the hospital, an unusual G8P[8] rotavirus (possibly acquired via bovine-to-human interspecies transmission) was detected with the identification...
of 11 gene segments for <3 hours. The findings indicate that Nanopore MinION sequencing may be used as a rapid diagnostic tool in cases of idiopathic severe gastroenteritis and in epidemiological studies to improve our understanding of the origin, genetic recombination, and burden of disease simultaneously. More studies using this method are needed to determine the efficacy and effectiveness of current vaccines based on global viral surveillance.

Acknowledgment

We would like to thank Miss Jihye Baek for support with data analysis.

Author contributions

Collection of clinical data and stool samples: Dae Yong Yi, Inseok Lim.
Conceptualization and design: Wonyong Kim, Alan C. Ward.
Data curation: Dae Yong Yi, Inseok Lim, Alan C. Ward, Wonyong Kim.
Formal analysis: Alan C. Ward, Wonyong Kim.
Investigation: Alan C. Ward, Wonyong Kim.
Laboratory work: Jong-Hwa Kim.
Methodology: Jong-Hwa Kim.
Project administration: Wonyong Kim.
Resources: Dae Yong Yi, Inseok Lim.
Software: Alan C. Ward, Wonyong Kim.
Statistical analysis: Wonyong Kim, Alan C. Ward.
Supervision: Inseok Lim, Wonyong Kim.
Validation: Dae Yong Yi, Alan C. Ward, Wonyong Kim.
Writing – original & draft: Wonyong Kim, Jong-Hwa Kim.
Writing – review & editing: Inseok Lim, Alan C. Ward.

References

[1] Hasso-Agopsowicz M, Ladva CN, Lopman B, et al. Global review of the age distribution of rotavirus disease in children aged < 5 years before the introduction of rotavirus vaccination. Clin Infect Dis 2019;69:1071–8.
[2] World Health Organization. Manual of Rotavirus Detection and Characterization Methods. No. WHO/V&B/08.17. Geneva: World Health Organization; 2009.
[3] Parashar UD, Nelson EA, Kang G. Diagnosis, management, and prevention of rotavirus gastroenteritis in children. BMJ 2013;347:f7204.
[4] Jeong S, Than VT, Lim I, et al. Differentiation of RotaTeq® vaccine strains from wild-type strains using NSP3 gene in reverse transcription polymerase chain reaction assay. J Virol Methods 2016;237:72–8.
[5] Thanh HD, Tran VT, Lim I, et al. Emergence of human G2P[4] rotaviruses in the post-vaccination era in South Korea: footprints of multiple interspecies re-assortment events. Sci Rep 2018;8:6011.
[6] Ward AC, Kim W. MinION™, new, long read, portable nucleic acid sequencing device. J Bacteriol Virol 2015;45:285–303.
[7] Quick J, Loman NJ, Duraffour S, et al. Real-time, portable genome sequencing for Ebola surveillance. Nature 2016;530:228–32.
[8] Sauvage V, Bozecau L, Cardoiz D, et al. Early MinION™ nanopore single-molecule sequencing technology enables the characterization of hepatitis B virus genetic complexity in clinical samples. PLoS One 2018;13:e0194366.
[9] Kirkwood CD. Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J Infect Dis 2010;202:S43–8.
[10] Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012;14:CD008521.
[11] Tissera MS, Cowley D, Bogdanovic-Sakran N, et al. Options for improving effectiveness of rotavirus vaccines in developing countries. Hum Vaccin Immunother 2017;13:921–7.
[12] Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007;119:11–8.
[13] Tissera MS, Cowley D, Bogdanovic-Sakran N, et al. Options for improving effectiveness of rotavirus vaccines in developing countries. Hum Vaccin Immunother 2017;13:921–7.